These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 16858817

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials.
    Lachin JM.
    Stat Med; 2004 May 30; 23(10):1519-21. PubMed ID: 15122730
    [Abstract] [Full Text] [Related]

  • 3. Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group.
    Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J, PhRMA Working Group.
    J Biopharm Stat; 2006 May 30; 16(3):275-83; discussion 285-91, 293-8, 311-2. PubMed ID: 16724485
    [Abstract] [Full Text] [Related]

  • 4. Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop.
    Krams M, Burman CF, Dragalin V, Gaydos B, Grieve AP, Pinheiro J, Maurer W, Gallo P.
    J Biopharm Stat; 2007 May 30; 17(6):957-64. PubMed ID: 18027207
    [Abstract] [Full Text] [Related]

  • 5. Overhauling clinical trials.
    Scott CT, Baker M.
    Nat Biotechnol; 2007 Mar 30; 25(3):287-92. PubMed ID: 17344876
    [No Abstract] [Full Text] [Related]

  • 6. Playing safe and preserving integrity: making the FDA model work.
    Wittes J.
    Stat Med; 2004 May 30; 23(10):1523-5. PubMed ID: 15122731
    [Abstract] [Full Text] [Related]

  • 7. FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.
    Chuang-Stein C, Beltangady M.
    J Biopharm Stat; 2010 Nov 30; 20(6):1143-9. PubMed ID: 21058110
    [Abstract] [Full Text] [Related]

  • 8. FDA perspective on clinical trial design for cardiovascular devices.
    Chen E, Sapirstein W, Ahn C, Swain J, Zuckerman B.
    Ann Thorac Surg; 2006 Sep 30; 82(3):773-5. PubMed ID: 16928481
    [No Abstract] [Full Text] [Related]

  • 9. The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it.
    O'Neill RT, Temple R.
    Clin Pharmacol Ther; 2012 Mar 30; 91(3):550-4. PubMed ID: 22318615
    [Abstract] [Full Text] [Related]

  • 10. FDA given new powers over data reporting to national clinical trials registry.
    Roehr B.
    BMJ; 2012 Oct 02; 345():e6629. PubMed ID: 23033375
    [No Abstract] [Full Text] [Related]

  • 11. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group.
    Gallo P, Anderson K, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J.
    J Biopharm Stat; 2010 Nov 02; 20(6):1115-24. PubMed ID: 21058107
    [Abstract] [Full Text] [Related]

  • 12. Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.
    Liu Q, Chi GY.
    J Biopharm Stat; 2010 Nov 02; 20(6):1178-219. PubMed ID: 21058114
    [Abstract] [Full Text] [Related]

  • 13. Data monitoring and large apparent treatment effects.
    Korn EL, Freidlin B, George SL.
    Control Clin Trials; 2004 Feb 02; 25(1):67-9; author reply 71-2. PubMed ID: 14980749
    [No Abstract] [Full Text] [Related]

  • 14. Regulatory perspectives on data monitoring.
    O'Neill RT.
    Stat Med; 2002 Oct 15; 21(19):2831-42. PubMed ID: 12325099
    [Abstract] [Full Text] [Related]

  • 15. The United States Food and Drug Administration guidelines on ambulatory blood pressure monitoring.
    Lipicky R.
    J Hypertens Suppl; 1991 Dec 15; 9(8):S59. PubMed ID: 1795204
    [Abstract] [Full Text] [Related]

  • 16. New clinical trials policy at FDA.
    Vastag B.
    Nat Biotechnol; 2006 Sep 15; 24(9):1043. PubMed ID: 16964196
    [No Abstract] [Full Text] [Related]

  • 17. Clinical trials in children--How are they implemented?
    Hirtz DG, Gilbert PR, Terrill CM, Buckman SY.
    Pediatr Neurol; 2006 Jun 15; 34(6):436-8. PubMed ID: 16765820
    [Abstract] [Full Text] [Related]

  • 18. Research infrastructure and IRB/FDA requirements.
    Cohen J.
    Med Health R I; 2000 Dec 15; 83(12):382-5. PubMed ID: 11190124
    [No Abstract] [Full Text] [Related]

  • 19. The drug approval process at the Food and Drug Administration. New biotechnology as a paradigm of a science-based activist approach.
    Miller HI, Young FE.
    Arch Intern Med; 1989 Mar 15; 149(3):655-7. PubMed ID: 2645844
    [No Abstract] [Full Text] [Related]

  • 20. Design and analysis of non-inferiority mortality trials in oncology.
    Carroll K, Milsted B, Lewis JA.
    Stat Med; 2004 Sep 15; 23(17):2771-4; author reply 2774-8. PubMed ID: 15316946
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.